{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:28:06Z","timestamp":1775550486186,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Mucopolysaccharidosis type I (MPS I) is the most common form of the MPS group of genetic diseases. MPS I results from a deficiency in the lysosomal enzyme \u03b1-l-iduronidase, leading to accumulation of undegraded heparan and dermatan sulphate glycosaminoglycan (GAG) chains in patient cells. MPS children suffer from multiple organ failure and die in their teens to early twenties. In particular, MPS I children also suffer from profound mental retardation and skeletal disease that restricts growth and movement. Neither brain nor skeletal disease is adequately treated by current therapy approaches. To overcome these barriers to effective therapy we have developed and tested a treatment called substrate deprivation therapy (SDT). MPS I knockout mice were treated with weekly intravenous injections of 1 mg\/kg rhodamine B for six months to assess the efficacy of SDT. Mice were assessed using biochemistry, micro-CT and a battery of behaviour tests to determine the outcome of treatment. A reduction in female bodyweight gain was observed with the treatment as well as a decrease in lung GAG. Behavioural studies showed slight improvements in inverted grid and significant improvements in learning ability for female MPS I mice treated with rhodamine B. Skeletal disease also improved with a reduction in bone mineral volume observed. Overall, rhodamine B is safe to administer to MPS I knockout mice where it had an effect on improving aspects of neurological and skeletal disease symptoms and may therefore provide a potential therapy or adjunct therapy for MPS I patients.<\/jats:p>","DOI":"10.3390\/diseases5010005","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T11:45:01Z","timestamp":1487850301000},"page":"5","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice"],"prefix":"10.3390","volume":"5","author":[{"given":"Ainslie","family":"Derrick-Roberts","sequence":"first","affiliation":[{"name":"Genetics and Molecular Pathology, SA Pathology, North Adelaide, SA 5006, Australia"},{"name":"Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA 5005, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7547-7653","authenticated-orcid":false,"given":"Matilda","family":"Jackson","sequence":"additional","affiliation":[{"name":"Genetics and Molecular Pathology, SA Pathology, North Adelaide, SA 5006, Australia"},{"name":"School of Molecular &amp; Biomedical Science, The University of Adelaide, Adelaide, SA 5005, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Pyragius","sequence":"additional","affiliation":[{"name":"Genetics and Molecular Pathology, SA Pathology, North Adelaide, SA 5006, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Byers","sequence":"additional","affiliation":[{"name":"Genetics and Molecular Pathology, SA Pathology, North Adelaide, SA 5006, Australia"},{"name":"Paediatrics and Reproductive Health, The University of Adelaide, Adelaide, SA 5005, Australia"},{"name":"School of Molecular &amp; Biomedical Science, The University of Adelaide, Adelaide, SA 5005, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of Lysosomal Storage Disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"ref_2","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill Companies Inc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0925-4439(98)00046-5","article-title":"Genotype-Phenotype Correlations in Mucopolysaccharidosis Type I Using Enzyme Kinetics, Immunoquantification and in Vitro Turnover Studies","volume":"1407","author":"Bunge","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1705569","article-title":"Biochemical Monitoring after Haemopoietic Stem Cell Transplant for Hurler Syndrome (Mpsih): Implications for Functional Outcome after Transplant in Metabolic Disease","volume":"39","author":"Church","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00019052-199904000-00007","article-title":"Bone Marrow Transplantation as Effective Treatment of Central Nervous System Disease in Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Adrenoleukodystrophy, Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly Syndromes, and Gaucher Disease Type III","volume":"12","author":"Krivit","year":"1999","journal-title":"Curr. Opin. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1302\/0301-620X.76B6.7983131","article-title":"Bone-Marrow Transplantation in Hurler's Syndrome. Effect on Skeletal Development","volume":"76","author":"Field","year":"1994","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","article-title":"Outcome of Unrelated Donor Bone Marrow Transplantation in 40 Children with Hurler Syndrome","volume":"87","author":"Peters","year":"1996","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-Replacement Therapy in Mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A Follow-up Study of Mps I Patients Treated with Laronidase Enzyme Replacement Therapy for 6 Years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1016\/S0021-9258(19)45842-0","article-title":"The Hurler Corrective Factor. Purification and Some Properties","volume":"246","author":"Barton","year":"1971","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1705401","article-title":"Haematopoietic Cell Transplantation (Hct) in Combination with Enzyme Replacement Therapy (Ert) in Patients with Hurler Syndrome","volume":"38","author":"Boelens","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","article-title":"Safety and Efficacy of Enzyme Replacement Therapy in Combination with Hematopoietic Stem Cell Transplantation in Hurler Syndrome","volume":"7","author":"Grewal","year":"2005","journal-title":"Genet. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1476-5381.2009.00565.x","article-title":"Genistein Reduces Glycosaminoglycan Levels in a Mouse Model of Mucopolysaccharidosis Type Ii","volume":"159","author":"Friso","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2009.06.013","article-title":"Genistein Reduces Lysosomal Storage in Peripheral Tissues of Mucopolysaccharide Iiib Mice","volume":"98","author":"Malinowska","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Malinowska, M., Wilkinson, F.L., Langford-Smith, K.J., Langford-Smith, A., Brown, J.R., Crawford, B.E., Vanier, M.T., Grynkiewicz, G., Wynn, R.F., and Wraith, J.E. (2010). Genistein Improves Neuropathology and Corrects Behaviour in a Mouse Model of Neurodegenerative Metabolic Disease. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014192"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"CR196","DOI":"10.12659\/MSM.881715","article-title":"Two-Year Follow-up of Sanfilippo Disease Patients Treated with a Genistein-Rich Isoflavone Extract: Assessment of Effects on Cognitive Functions and General Status of Patients","volume":"17","author":"Piotrowska","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.curtheres.2008.04.002","article-title":"Genistin-Rich Soy Isoflavone Extract in Substrate Reduction Therapy for Sanfilippo Syndrome: An Open-Label, Pilot Study in 10 Pediatric Patients","volume":"69","author":"Piotrowska","year":"2008","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22643","article-title":"Genistein in Sanfilippo Disease: A Randomized Controlled Crossover Trial","volume":"71","author":"Valstar","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/8904_2011_87","article-title":"The Use of Elevated Doses of Genistein-Rich Soy Extract in the Gene Expression-Targeted Isoflavone Therapy for Sanfilippo Disease Patients","volume":"5","author":"Malinova","year":"2012","journal-title":"JIMD Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","article-title":"High Dose Genistein Aglycone Therapy Is Safe in Patients with Mucopolysaccharidoses Involving the Central Nervous System","volume":"109","author":"Kim","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the Range of Joint Motion in Seven Patients with Mucopolysaccharidosis Type Ii During Experimental Gene Expression-Targeted Isoflavone Therapy (Get It)","volume":"155A","author":"Marucha","year":"2011","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ymgme.2010.06.008","article-title":"Trans-Generational Exposure to Low Levels of Rhodamine B Does Not Adversely Affect Litter Size or Liver Function in Murine Mucopolysaccharidosis Type IIIA","volume":"101","author":"Roberts","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2007.06.016","article-title":"Improvement in Behaviour after Substrate Deprivation Therapy with Rhodamine B in a Mouse Model of Mps IIIA","volume":"92","author":"Roberts","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/01.pdr.0000233037.00707.da","article-title":"Inhibition of Glycosaminoglycan Synthesis Using Rhodamine B in a Mouse Model of Mucopolysaccharidosis Type Iiia","volume":"60","author":"Roberts","year":"2006","journal-title":"Pediatr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","article-title":"Can Mucopolysaccharidosis Type I Disease Severity Be Predicted Based on a Patient\u2019s Genotype? A Comprehensive Review of the Literature","volume":"5","author":"Terlato","year":"2003","journal-title":"Genet. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo Syndrome: A Mini-Review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","article-title":"Why Are Behaviors of Children Suffering from Various Neuronopathic Types of Mucopolysaccharidoses Different?","volume":"75","author":"Wegrzyn","year":"2010","journal-title":"Med. Hypotheses"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1203\/00006450-197911000-00018","article-title":"Alpha-l-Iduronidase Deficiency in a Cat: A Model of Mucopolysaccharidosis I","volume":"13","author":"Haskins","year":"1979","journal-title":"Pediatr. Res."},{"key":"ref_29","first-page":"244","article-title":"Canine Alpha-l-Iduronidase Deficiency. A Model of Mucopolysaccharidosis I","volume":"109","author":"Shull","year":"1982","journal-title":"Am. J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/6.4.503","article-title":"Murine Mucopolysaccharidosis Type I: Targeted Disruption of the Murine Alpha-l-Iduronidase Gene","volume":"6","author":"Clarke","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-0004.1998.tb02745.x","article-title":"Murine Mps I: Insights into the Pathogenesis of Hurler Syndrome","volume":"53","author":"Russell","year":"1998","journal-title":"Clin. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.brainres.2007.10.036","article-title":"Progression of Multiple Behavioral Deficits with Various Ages of Onset in a Murine Model of Hurler Syndrome","volume":"1188","author":"Pan","year":"2008","journal-title":"Brain Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1089\/hum.2013.141","article-title":"Lentiviral-Mediated Gene Therapy Results in Sustained Expression of Beta-Glucuronidase for up to 12 Months in the Gus(Mps\/Mps) and up to 18 Months in the Gus(Tm(L175f)Sly) Mouse Models of Mucopolysaccharidosis Type VII","volume":"25","author":"Pyragius","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ymgme.2012.03.022","article-title":"Skeletal Response to Lentiviral Mediated Gene Therapy in a Mouse Model of Mps VII","volume":"106","author":"Macsai","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/0003-2697(73)90377-1","article-title":"New Method for Quantitative Determination of Uronic Acids","volume":"54","author":"Blumenkrantz","year":"1973","journal-title":"Anal. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/bj0780151","article-title":"Studies on Glucosaminidase. 4. The Fluorimetric Assay of N-Acetyl-Beta-Glucosaminidase","volume":"78","author":"Leaback","year":"1961","journal-title":"Biochem. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A Simple Method for the Isolation and Purification of Total Lipides from Animal Tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1471-4159.1980.tb12515.x","article-title":"The Use of Sep-Pak C18 Cartridges During the Isolation of Gangliosides","volume":"35","author":"Williams","year":"1980","journal-title":"J. Neurochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2016.04.002","article-title":"N-Butyldeoxynojirimycin Treatment Restores the Innate Fear Response and Improves Learning in Mucopolysaccharidosis IIIA Mice","volume":"118","author":"Kaidonis","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymgme.2016.09.003","article-title":"Reversal of Established Bone Pathology in Mps Vii Mice Following Lentiviral-Mediated Gene Therapy","volume":"119","author":"Panir","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/15563658708992660","article-title":"Acute Exposure to Rhodamine B","volume":"25","author":"Dire","year":"1987","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"ref_42","first-page":"523","article-title":"Rhodamine B Ingestion as a Cause of Fluorescent Red Urine","volume":"143","author":"Kelner","year":"1985","journal-title":"West J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.05.079","article-title":"Characterization of a C57bl\/6 Congenic Mouse Strain of Mucopolysaccharidosis Type IIIA","volume":"1104","author":"Crawley","year":"2006","journal-title":"Brain Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A Contradictory Treatment for Lysosomal Storage Disorders: Inhibitors Enhance Mutant Enzyme Activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.brainresbull.2007.07.018","article-title":"Characterization of an Immunodeficient Mouse Model of Mucopolysaccharidosis Type I Suitable for Preclinical Testing of Human Stem Cell and Gene Therapy","volume":"74","author":"Nelson","year":"2007","journal-title":"Brain Res. Bull."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/5\/1\/5\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:28:59Z","timestamp":1760207339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/5\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["diseases5010005"],"URL":"https:\/\/doi.org\/10.3390\/diseases5010005","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]}}}